MAHA report on children's health highlights harms of ultraprocessed foods – a food scientist explains the research
On May 22, 2025, the White House released a new report highlighting what it claims are the causes of chronic disease in children.
The report fleshes out many of the themes that have emerged as priorities for the Make America Healthy Again, or MAHA, movement promoted by Health and Human Services Secretary Robert F. Kennedy Jr.
One major area of focus is the negative health effects of ultraprocessed foods. The report points to the prevalence of ultraprocessed foods in the American diet as a key contributor to chronic illness in children and cites research that finds that nearly 70% of children's diets and 50% of pregnant and postpartum women's diets in the U.S. consist of ultraprocessed foods.
The Conversation U.S. asked Paul Dawson, a food scientist at Clemson University, to explain how the government's stance on the harms of ultraprocessed foods squares with the science.
Concerns that ingredients used by food manufacturers can contribute to chronic illness first emerged in the 1970s and 1980s, when research began linking processed food consumption to increasing rates of obesity, type 2 diabetes and cardiovascular disease. The term 'ultraprocessed food' dates back to the 1980s and was used to describe convenience foods and snacks that contained high amounts of additives and had low nutritional value.
As research on the health effects of ultraprocessed foods began to build, experts in public health and the food industry have debated the meaning of the term. Increasingly, researchers are settling on defining ultraprocessed foods based on a framework called the Nova Food Classification System, created in 2009 by nutrition researchers in Brazil. The framework assigns foods to one of four groups based on the level of processing they undergo:
Group 1 - Unprocessed or minimally processed foods: This category includes raw fruits, vegetables and meats that may be cleaned, frozen or fermented but remain close to their natural state.
Group 2 - Processed culinary ingredients: Think salt, sugar, oils and other ingredients extracted from nature and used to cook and flavor foods.
Group 3 - Processed foods: Foods in this category are made by adding ingredients like salt or sugar to Group 1 items — for example, canned vegetables or cheese.
Group 4 - Ultraprocessed foods: These are mostly foods that contain ingredients not found in a typical kitchen, such as hydrogenated oils, modified starches, flavor enhancers, color additives and preservatives. Examples include chips, sodas, candy bars and many frozen meals, which are designed to be hyper-palatable and often nutrient-poor.
A growing body of research links ultraprocessed foods with many negative health outcomes, including obesity, type 2 diabetes, cardiovascular disease, cancer and cognitive decline. One issue is that these products are typically high in added sugar, sodium, saturated fats and chemical additives, and low in fiber, vitamins and essential micronutrients.
But some studies also suggest that what makes these foods harmful isn't just the ingredients but also how they're made. That's because the industrial processing of fats and starches can produce harmful compounds. For example, a substance called acrolein, formed when oils are heated at high temperatures, has been linked to DNA damage. Studies are also finding that microparticles from packaging and plastics, now found in air, water and food, may disrupt the gut microbiome, a key player in immune and metabolic health.
One drawback of nutrition studies is that they often rely on self-reported dietary data, which can be inaccurate. They can also have confounding factors that are difficult to account for, such as lifestyle patterns. However, the consistency of the findings across diverse populations gives credence to the growing concerns about ultraprocessed foods.
An important caveat, however, is that not all ultraprocessed foods are created equal. They vary in how nutritious they are, and some ultraprocessed foods play an important role for vulnerable populations. For example, foods containing the slow-release carbohydrate sweetener sucromalt help people with diabetes prevent blood sugar spikes, and hypoallergenic infant formula can be lifesaving for infants that cannot digest milk at a young age.
The report echoes key themes of the 2020–2025 Dietary Guidelines for Americans, a document jointly published by the Departments of Agriculture and Health and Human Services every five years. Both the MAHA report and the federal guidelines encourage the consumption of nutrient-dense, whole foods.
One critical difference between them is that the 2020-2025 dietary guidelines make no mention of ultraprocessed foods. Some public health experts have noted that this omission may reflect food industry influence.
Kennedy has stated that a follow-up report outlining a strategy and potential policy reforms for addressing childhood chronic illness will be released in mid-August 2025.
However, change is unlikely to be straightforward. Ultraprocessed foods represent a significant industry, and policies that challenge their prominence may encounter resistance from influential commercial interests. For decades, U.S. agricultural subsidies, food policy and consumers have supported the mass production and consumption of ultraprocessed foods. Reversing their overconsumption will require structural shifts in how food is produced, distributed and consumed in the U.S.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Paul Dawson, Clemson University
Read more:
Ultraprocessed foods – like cookies, chips, frozen meals and fast food – may contribute to cognitive decline
Foods high in added fats and refined carbs are like cigarettes – addictive and unhealthy
Nutrition Facts labels have a complicated legacy – a historian explains the science and politics of translating food into information
Paul Dawson receives funding from the USDA.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
The Wahconah Group Seeks Strategic Investment to Scale Across Both Tactical Services and Loyalty Brand Divisions
The Wahconah Group seeks funding to accelerate its national and global expansion plans. Fayetteville, North Carolina, June 04, 2025 (GLOBE NEWSWIRE) -- The Wahconah Group, an innovation-driven company specializing in apparel design, manufacturing, and services for both tactical and retail markets, is officially seeking funding and strategic partners to support its rapid national and international expansion. With two divisions, Tactical Services and Loyalty Brand Products, both experiencing transformative growth, the company is now looking to streamline, expedite, and scale that success through investment. Wahconah GroupThe funding sought will support both divisions in their respective scale-ups: building infrastructure to service new regions, hiring a recently laid-off group of experienced American manufacturing professionals, and investing in marketing, logistics, and technology systems to support national and international growth. On the Loyalty Brand Products side, Wahconah has already built a solid reputation throughout the Northeast, serving luxury clients, global conglomerates, private high schools, and prestigious colleges, with custom-branded merchandise and apparel, including acclaimed brand collections. The company is now actively duplicating that model across the U.S., and potentially worldwide. Meanwhile, on the Tactical Services front, Wahconah has just secured a powerful manufacturing partnership with an international firm boasting 60 years of experience, expanding its capabilities in tactical manufacturing. That collaboration, along with a newly acquired United Labs certification, has allowed Wahconah to extend services beyond elite military units to include certified cleaning and repair of firefighter gear, a sector in critical need of health-focused solutions. 'Our process doesn't just restore; it enhances,' said CEO Isaac Crawford. 'Uniforms last 25 to 30 cycles with our cleaning process. That's lab-tested. We're here to help protect the protectors: firefighters, military, and beyond.' With rising cancer rates among firefighters linked to contaminated gear, Wahconah's certified, health-focused uniform care is now a necessity, not a luxury. The timing for scaling couldn't be better: the company is positioned to become a national leader in protective apparel maintenance and tactical manufacturing just as awareness and demand reach critical mass. As the U.S. approaches its 250th anniversary, Loyalty Brand Products is also planning several high-profile initiatives and partnerships. From its roots in high-tech innovation to its on-the-ground impact in apparel accessories and services, Wahconah's business strategy is built on scalable, sustainable solutions. 'For five years, we've done this without outside funding. We've proven the model. We've created jobs. Now we're building the team and infrastructure to grow further,' Crawford confirmed. 'Some investments are a leap of faith. This isn't one of them.' Interested investors and strategic partners are encouraged to reach out directly to explore funding opportunities aligned with the company's values and goals. The Wahconah Group offers a rare chance to join a dual-division company already in motion, delivering results, creating value, and reshaping the future of American apparel and protective gear. Media Contact Name: The Wahconah Group Email: info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Launch of a capital increase with preferential subscription rights for nearly 5 million euros
Press release Launch of a capital increase with preferential subscription rights for nearly 5 million euros Issuance of new shares for an initial total amount of around €5.0 million, with shareholders maintaining their preferential subscription rights (DPS), which may be increased to around €5.7 million if the extension clause is exercised (the 'Offer'). Intentions and commitment to subscribe by existing shareholders and Vatel Capital, as a new institutional investor, for a total amount of approximately 3.7M€, already representing 76,4% of the transaction. Subscription price for the new shares set at €1.40, representing a 22.6% discount to the closing price of the CROSSJECT share on June 3, 2025 (€1.808) and a 21.3% discount to the theoretical value of the CROSSJECT share ex-rights. Subscription period from June 12, 2025 to June 20, 2025 included. Dijon, France 4 June 2025 (8.10 PM CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in advanced phases of development and registration of ZEPIZURE®, launches a capital increase with preferential subscription rights ('DPS'), for an initial total amount of 4,978,678.60 euros ('the Offer'), which may be increased to 5,725,479.20 euros if the extension clause is exercised. Objectives of the capital increase As announced on May 7 and May 20, CROSSJECT continues to focus on the preparation of the EUA submission to the FDA, and remains on schedule to finalize production of the validation batches in June. CROSSJECT will transfer these data as the final addition into the ZEPIZURE® EUA submission platform. CROSSJECT expects a first confirmation of receipt from the FDA one month after submission. In addition, CROSSJECT has started a first manufacturing cycle of EUA batches, intended for the first delivery of the CHEMPACK program as part of the US national preparedness against chemical threats, in agreement with its American partner, the Biomedical Advanced Research and Development Authority (BARDA). CROSSJECT also continues to allocate a significant portion of its resources to its infrastructure in the United States and to its other product candidates. As planned, CROSSJECT is pursuing the other stages in the development of ZEPIZURE® for its second NDA filing in the second quarter of 2026, as well as developments relating to ZENEO Adrenaline and ZENEO Hydrocortisone. The Company intends to use the net proceeds of the issue as follows: - Approximately 60% will be allocated to the final development phases of ZEPIZURE® and the start-up of the initial production stages, including the building up of related inventories, prior to any reimbursement by its American partner; - Approximately 40% will be used to finance R&D for its other projects, ZENEO® Adrenaline and ZENEO® Hydrocortisone, to repay certain financial creditors, and to cover general and administrative expenses and corporate development costs, particularly in the United States. In the event of the Offer being limited to 75% of the issue, i.e. around 3.7 million euros, CROSSJECT will allocate the net proceeds to the above activities on a prorata basis, giving priority to activities linked to the registration and production of ZEPIZURE®. With the net proceeds of the issue, the Company estimates that its net working capital would be sufficient to meet its obligations until the end of 2025, assuming the first payments from its American partner following the first deliveries. In order to preserve its financial flexibility and ensure its cash position in 2025 until receipt of these first payments, expected from the third quarter, the Company continues to study dilutive and non-dilutive financing alternatives. The Company could also receive additional funds from the exercise of the warrants issued on December 13, 2024, up to a maximum amount of around €10.2 million, to meet additional financing needs. Future payments from its US partner beyond 2025 will be a major contribution to the Company's financing needs. Terms and conditions of the capital increase Nature and legal framework of the transaction The capital increase involves the issue of new shares with maintenance of the shareholders' preferential subscription rights. The CEO, acting on the basis of the 7th and 13th extraordinary resolutions of the Combined General Meeting of June 27, 2024, in accordance with the authorization granted to him by the Supervisory Board on May 19, 2025, and pursuant to the sub-delegation granted to him by the Executive Board on May 19, 2025, decided on June 4, 2025 to carry out a capital increase through the issue of ordinary shares with preferential subscription rights, the terms of which are detailed in this press release. Share capital – Number of shares issued CROSSJECT's share capital comprises 46,230,596 fully subscribed and paid-up shares with a par value of €0.1 each, listed on the Euronext Growth market of Euronext Paris. Based on the number of shares currently outstanding, 3,556,199 new shares will be issued (which may be increased to 4,089,628 new shares if the extension clause is exercised), on the basis of 1 new share for every 13 existing shares held (13 preferential subscription rights will entitle the holder to subscribe for 1 new share). The initial issue of 3,556,199 new ordinary shares with a par value of €0.1, at a price of €1.40 each, would represent a capital increase of a nominal amount of €355,619.90, together with a share premium of €4,623,058.70, giving gross proceeds of €4,978,678.60. Extension clause In the event of oversubscription and full exercise of the extension clause, the number of ordinary shares that could be issued would be increased to 4,089,628 shares, representing a capital increase of a nominal amount of €408,962.80 and a share premium of €5,316,516.40, i.e. gross proceeds of €5,725,479.20. Subscription price The subscription price per new share is €1.40, and must be fully paid up in cash at the time of subscription. The issue price of €1.40 per share represents a discount of 22.6% to the closing price of the CROSSJECT share on June 3, 2025 (€1.808) and a discount of 21.3% to the theoretical value of the CROSSJECT share ex-rights. The issue price represents a discount of 22,6% and 19,2% compared to the closing price on June 3, 2025, the 30 day weighted average trading price respectively and a premium of 3,3% over the 60 day weighted average trading price. Subscription terms Subscription opening and closing dates from June 12, 2025 to June 20, 2025 inclusive. Subscriptions on an irreducible basis Subscription of the new shares is reserved by preference for existing shareholders, or assignees of their preferential subscription rights, who may subscribe on an irreducible basis, at the rate of 1 new share for 13 preferential subscription rights, without taking fractions into account. Shareholders or assignees of their preferential subscription rights who do not hold a sufficient number of existing shares or preferential subscription rights to obtain a whole number of new shares may buy or sell the number of preferential subscription rights needed to reach the multiple leading to a whole number of new shares. Subscriptions on a reducible basis Shareholders will have the right to subscribe for shares on a reducible basis, in proportion to their rights and up to the number of shares they request. At the same time as they submit their irreducible subscriptions, shareholders or assignees of their rights may subscribe for as many new shares as they wish, in addition to the number of new shares resulting from the exercise of their irreducible rights. Any new shares not taken up by irrevocable subscriptions will be distributed and allocated to reducible subscribers. Subscription orders on a reducible basis will be served up to the limit of their numbers. A notice published by Euronext will make known, where applicable, the allocation scale for subscriptions on a reducible basis. Exercise of preferential subscription rights To exercise their preferential subscription rights, holders must submit a request to their authorized financial intermediary at any time between June 12, 2025 and June 20, 2025 inclusive, and pay in full the amount of their subscription. Each subscription must be accompanied by a payment of the subscription price in cash or by offsetting liquid and due claims on the Company. Subscriptions that have not been paid up in full will be cancelled, without the need for formal notice. Preferential subscription rights not exercised by the close of the subscription period will automatically lapse. Preferential subscription rights must be exercised by their beneficiaries, at risk of being cancelled before the end of the subscription period, i.e. June 20, 2025. Listing of preferential subscription rights The preferential subscription rights will be detached on June 10, 2025 for the benefit of holders of existing shares recorded in their securities account at the end of the accounting day of June 9, 2025, on the basis of one preferential subscription right per existing share of the Company. They will be listed and traded on Euronext Growth under ISIN code FR00140100I2 from June 10, 2025 to June 18, 2025 included. Theoretical value of the preferential subscription right €0.03 based on the closing price of the Company's shares on June 3, 2025, i.e. €1.808. The subscription price of €1.40 per share represents a discount of 21.30% to the theoretical value of the share after detachment of the right. Paying agents - Subscription payments Funds paid in support of cash subscriptions will be centralized by Crédit Industriel et Commercial (CIC Market Solutions - Émetteur Adhérent Euroclear n°025) 6 avenue de Provence 75452 Paris Cedex 9. Preferential subscription rights detached from treasury shares held by the Company In accordance with article L. 225-210 of the French Commercial Code, the Company may not subscribe for its own shares. Preferential subscription rights detached from shares owned by the Company will be sold on the market before the close of the preferential subscription rights trading period. Free subscription requests In addition to the possibility of subscribing on an irreducible and reducible basis in accordance with the terms and conditions set out above, any individual or legal entity, whether or not holding preferential subscription rights, may subscribe to this capital increase on an unrestricted basis. Persons wishing to subscribe on a voluntary basis must send their request to Crédit Industriel et Commercial (CIC Market Solutions - Émetteur Adhérent Euroclear n°025) 6 avenue de Provence 75452 Paris Cedex 9, OR to their authorized financial intermediary at any time during the subscription period and pay the corresponding subscription price. In accordance with the provisions of Article L. 225-134 of the French Commercial Code, unrestricted subscriptions will only be taken into account if the irreducible and reducible subscriptions have not absorbed the entire capital increase, it being specified that the Executive Board will have the option of freely allocating the unsubscribed shares, in whole or in part, among the persons (shareholders or third parties) of its choice who have made unrestricted subscription requests. Indicative timetable for the operation The table below sets out the expected timetable for the transaction as at the date of this press release: June 4, 2025 Decision by the Chairman of the Executive Board to carry out a capital increase with preferential subscription rights, and to set the terms and conditions of the transaction. Press release announcing the transaction June 6, 2025 Publication of the information notice in the BALO June 10th 2025 Detachment of preferential subscription rights and start of trading of preferential subscription rights on Euronext Growth Paris June 12th, 2025 Opening of the subscription period June 18, 2025 End of DPS trading period June 20, 2025 End of subscription period june 24, 2025 Decision to exercise the extension clause Press release announcing the results of the Offer june 25, 2025 Publication by Euronext Paris of the notice of admission of the final amount of the capital increase and the allocation scale for subscriptions subject to reduction (reducible basis) june 27, 2025 Issue and settlement of new shares Admission and start of trading of the new shares on Euronext Growth Paris The above timetable will be followed by the regulatory publications of the new total number of shares and the usual legal formalities. Undertaking by the Company to refrain from trading in the Company's shares and lock-up agreement The Company has entered into a lock-up agreement for a period expiring 90 calendar days following the settlement-delivery date of the new shares, subject to certain customary exceptions. Commitment and subscription intentions The holder of convertible bonds (OCAs) affiliated with Heights Capital Management, Inc ("Heights") has indicated its intention to subscribe to the proposed capital increase by offsetting against its claim of 555,645 euros corresponding to the cash redemption of the final maturity date of the convertible bonds of April 28, 2025, representing 11.1% of the capital increase (excluding the exercise of the Extension Clause). Under the terms of a subscription undertaking signed on June 4, 2025, Vatel Capital ("Vatel Capital"), an investor who was not a shareholder at the date of this press release, has irrevocably undertaken to subscribe to the capital increase on an irreducible and reducible basis for a total amount of 2,000,000 euros, representing 40.1% of the capital increase (excluding the exercise of the Extension Clause). In accordance with its intention announced on May 20, 2025, Gemmes Venture, the Company's reference shareholder, has undertaken to underwrite the Offer up to the amount necessary for its completion (i.e. 75% of the initial issue amount). In order to enable Heights and Vatel Capital to participate in the issue, Gemmes Venture has also undertaken to sell its DPS for a price of 1 euro per block of DPS to Heights and Vatel Capital1 . At the same time, Gemmes Venture will subscribe to the planned capital increase on an irreducible basis for the balance of its preferential subscription rights, i.e. 276,068, and on a reducible basis for an amount equivalent to what it would have obtained by exercising its preferential subscription rights, i.e. a total amount of 1,250,000 euros, representing 25.1% of the capital increase (excluding the exercise of the Extension Clause). In total, the intentions and commitments of these two existing shareholders and of Vatel Capital to subscribe for the shares on an irreducible and reducible basis represent 3,805,645 euros, or 76.4% of the planned capital increase (excluding the extension clause). Guarantee The offer will not be subject to a performance guarantee within the meaning of article L.225-145 of the French Commercial Code. Ownership date and listing of the new shares The new shares, which will be subject to all the provisions of the Articles of Association, will be created with dividend rights. They will be assimilated to existing shares as soon as they are issued. They will be the subject of an application for admission to trading on Euronext Growth. They will be listed on the same line as existing shares and will be fully assimilated to them as soon as they are admitted for trading. Settlement-delivery and admission of the new shares to trading on Euronext Growth Paris is scheduled for June 27, 2025. Undertaking to retain shares None. Impact of the capital increase on shareholders' equity per share The table below summarizes the dilutive impact of the capital increase in euros on shareholders' equity per share under different dilution scenarios linked to the issue: Impact on shareholders' equity in euros per share Non-diluted basis Primary diluted basis(a) Total diluted basis with conversion/amortisation of OCAs(b) Case 1 Case 2 Before issue of new shares -0,05 € 0,16 € 0,27 € 0,25 € After issue of 3,556,199 new shares (100% of the Offer) 0,06 € 0,24 € 0,34 € 0,32 € After issue of 2,667,150 new shares (i.e. 75% of the Offer in the event of limitation) 0,03 € 0,22 € 0,32 € 0,30 € After issue of 4,089,628 new shares (i.e. 115% of the Offer in the event of exercise of the extension clause) 0,07 € 0,25 € 0,35 € 0,33 € (a) Reflects the dilution of : 950,700 shares allocated free of charge by the Company during the vesting period 3,635,556 BSAs issued in December 2024 may give the right to subscribe for a total of 4,544,445, shares at a price of €2.25 per share (four BSAs giving the right to subscribe for five ordinary shares). (b) Reflects the exercise of the bonds convertible into new shares and redeemable for shares (OCAs) issued on February 28, 2024 and February 7, 2025, in accordance with the terms and conditions set out below. The dilution cases relating to the OCAs are based on the assumptions set out below: Case 1 In the event of conversion of all the OCAs at the conversion price of 1.677 euros (subject to adjustment)The Company does not redeem any shares. Case 2 The OCA holder chooses not to convert any OCAs into Company elects to redeem all the OCAs in shares, and the redemption1 euro (subject to the investor holding 9.99% of the Company's capital). Common assumptions Calculations based on the number of shares making up the Company's share capital at the date of this press release, i.e. 46,230,596 shares. The holder of the convertible bonds never holds more than 9.99% of the Company's share capital at each conversion or redemption into shares. Impact of the capital increase on the situation of shareholders who do not subscribe to the transaction For information purposes, the impact of the capital increase on the situation of a shareholder holding 1% of CROSSJECT's share capital prior to the capital increase and not subscribing to it would be as shown below. Shareholding of a shareholder holding 1% of the capital prior to the offer Non-diluted basis Primary diluted basis(a) Total diluted basis with conversion/amortisation of OCAs(b) Case 1 Case 2 Before issue of new shares 1,00 % 0,89% 0,82% 0,78% After issue of 3,556,199 new shares (100% of the Offer) 0.93% 0.84% 0,77% 0,73% After issue of 2,667,150 new shares (i.e. 75% of the Offer in the event of limitation) 0,95% 0,85% 0,78% 0,74% After issue of 4,089,628 new shares (i.e. 115% of the Offer in the event of exercise of the extension clause) 0,92% 0,83 0,77% 0,73% (a) Reflects the dilution of : 950,700 shares allocated free of charge by the Company during the vesting period 3,635,556 BSAs issued in December 2024 may give the right to subscribe for a total of 4,544,445 shares at a price of 2.25 euros per share (four BSAs giving the right to subscribe for five ordinary shares). (b) Reflects the cases of exercise of the Bonds Convertible into New and Redeemable Shares (OCAs) issued on February 28, 2024 and February 7, 2025, in accordance with the terms specified above. CROSSJECT is being advised in this transaction by D'Hoir Beaufre Associé Market Solutions is acting as Lead Manager and Bookrunner. Risk factors relating to the Offer Shareholders who do not exercise their preferential subscription rights will see their stake in the Company's capital diluted; The market for preferential subscription rights may offer only limited liquidity and be subject to high volatility; The market price of the Company's shares could fluctuate and fall below the subscription price of the new shares from the announcement of the offer, during the subscription period or at any time after the close of the offer; The volatility and liquidity of the Company's shares could fluctuate significantly; In the event of a fall in the market price of the Company's shares, preferential subscription rights could lose their value. Shareholders could see their interest in the Company's share capital diluted in the event of a new public offering. Issuer risk factors The Company draws the public's attention to the risk factors relating to its activities presented in section 8. Analysis of business trends in relation to the volume and complexity of business in its 2024 annual report, online on the Company's website ( and in notes 3. a) "Going concern" and 27 "Events after the period-end" to the 2024 annual financial statements. Warning Insofar as the amount of the Offer is less than €8 million (calculated over a 12-month period), the planned issue will not give rise to a prospectus approved by the AMF. About CROSSJECT CROSSJECT SA (Euronext: ALCJ; is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. CROSSJECT is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with BARDA. The Company's versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare skin or even through clothing. The Company's other products in development mainly include solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications. * This project has been supported in whole or in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; BARDA, under contract number 75A50122C00031. *** For further information, please contact: Investor Relationsinvestors@ 1 Gemmes Venture will sell 3,741,536 preferential subscription rights to Heights for a price of 1 euro, to enable it to subscribe to the planned capital increase on an irreducible basis, by offsetting its entire claim (taking into account the preferential subscription rights already held by Heights).Gemmes Venture will also sell 7,301,880 preferential subscription rights at a price of 1 euro to Vatel Capital to enable it to subscribe 561,683 new shares to the planned capital increase. Vatel Capital also reserves the right to acquire other preferential subscription rights on the market and will subscribe to the balance of its subscription commitment on a reducible basis. Attachment Launch of a capital increaseSign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Everything Got Worse During COVID
Last week, Reason's Billy Binion reported on some undersung good news: American murder rates are falling fast. This year could end up being the least violent year on record. This is, of course, a welcome development by itself. It's an especially laudatory trend, coming as it does on the heels of a massive murder spike during the pandemic, when homicides rose by 30 percent in the average U.S. city. The COVID crime wave is well understood by now. The all-cause rise in mortality during the pandemic is a little less appreciated. No matter how you slice it, America during COVID was a sicker, deadlier, more dangerous, and generally more dysfunctional place. Between 2019 and 2021, drug overdose went up some 55 percent and traffic fatalities rose 20 percent. These fatalities, alongside an estimated 1.2 million COVID deaths, helped push the country's death rate from 723.6 deaths per 100,000 people in 2019 to a high of 879.7 in 2021. Remarkably, only suicides seemed to have resisted the rising death trend, falling in 2020 before rising slightly above pre-pandemic levels in 2021. Mercifully, murders, traffic deaths, and overdoses are now all falling from their pandemic-era highs. (Suicides continue to climb.) But the overall age-adjusted death rate in 2023 (the last year for which we have complete data) is still above pre-COVID levels. COVID was certainly a public health disaster. The effort to combat it by pausing day-to-day social and economic life created its own disasters for people's health and well-being. How much of that latter disaster can be blamed on formal lockdowns and stay-at-home orders vs. ubiquitous (albeit voluntary) public health guidance to socially distance, to individuals' own natural reticence to be around each other in the middle of a pandemic is a worthy topic of debate. The top-line takeaway remains the same: going to work, church, or one's chosen "third place" goes a long way toward keeping people alive and sane. When sociability falls, antisocial behaviors spike. Governments' massive emergency expansion of the welfare state seemingly did little to ease the pain. Stimulus checks, cash transfers, tax credits, and expanded unemployment insurance pushed the poverty rate down. This on-paper improvement in people's financial condition couldn't stop them from driving more dangerously, doing more dangerous drugs, and killing each other more. Shutting down whole swaths of the economy, and then paying people to stay home, caused its own ill effects. The U.S. Misery Index—a combined measure of the unemployment and inflation rates— rose from 5.44 in 2019 to a peak of 11.65 in 2022. It's currently at 6.98. At his confirmation hearing to be director of the National Institutes of Health (NIH), Jay Bhattacharya was unapologetic about his prior vocal criticism of society-wide stay-at-home orders. States like Florida, with its lighter, shorter lockdown, ended the pandemic with a lower all-cause mortality than archrestrictionist California, he noted. It's a sign of the times that none of the Democrats during that hearing pushed back on this particular point. If history is any guide, the pandemic will quickly fade from the collective memory. One hopes that this particular lesson learned—that society can't just be turned off and on again without courting disaster—sticks. The post Everything Got Worse During COVID appeared first on